278
Participants
Start Date
June 12, 2017
Primary Completion Date
February 26, 2020
Study Completion Date
March 5, 2020
ALKS 5461
Samidorphan + buprenorphine, administered sublingually
ALKS 5461 Placebo
Placebo tablet, administered sublingually
Alkermes Investigational Site, Richmond
Alkermes Investigational Site, Noble Park
Alkermes Investigational Site, Frankston
Alkermes Investigational Site, Mount Kisco
Alkermes Investigational Site, Jamaica
Alkermes Investigational Site, Allentown
Alkermes Investigational Site, Pikesville
Alkermes Investigational Site, Decatur
Alkermes Investigational Site, Atlanta
Alkermes Investigational Site, Jacksonville
Alkermes Investigational Site, Orlando
Alkermes Investigative Site, Palm Bay
Alkermes Investigational Site, Hollywood
Alkermes Investigational Site, Lauderhill
Alkermes Investigational Site, Memphis
Alkermes Investigational Site, Canton
Alkermes Investigational Site, Cincinnati
Alkermes Investigational Site, O'Fallon
Alkermes Investigational Site, Little Rock
Alkermes Investigational Site, Oklahoma City
Alkermes Investigational Site, DeSoto
Alkermes Investigational Site, Dallas
Alkermes Investigational Site, Tucson
Alkermes Investigational Site, Pico Rivera
Alkermes Investigational Site, Los Alamitos
Alkermes Investigational Site, Sherman Oaks
Alkermes Investigative Site, Upland
Alkermes Investigational Site, Oceanside
Alkermes Investigational Site, Redlands
Alkermes Investigational Site, Temecula
Alkermes Investigational Site, Santa Ana
Alkermes Investigative Site, Bellevue
Alkermes Investigational Site, Woodstock
Alkermes Investigational Site, San Juan
Alkermes Investigational Site, San Juan
Lead Sponsor
Alkermes, Inc.
INDUSTRY